Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT03760575
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Mesotheliomas Pleural

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    Pembrolizumab 200mg via IV infusion every 3 weeks for 2 cycles 3 pre-surgery, for 4 cycles post-surgery and then every 3 weeks during maintenance.
  • Indocyanine Green (ICG) Image-Guided Surgery — PROCEDURE
    Standard surgery with image guided resection.
  • Cisplatin — DRUG
    75 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.
  • Pemetrexed — DRUG
    500 mg/m2 every 3 weeks via IV infusion for 4 cycles post-surgery.

Study Details

The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).

Key Dates

Start date
Jan 10, 2023
Status verified
Dec 2025
Primary completion
Feb 1, 2027
Completion
Feb 1, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab with image-guided surgery and chemotherapy

Primary Outcome Measure

Study related adverse events (AEs) [ Time Frame: Each subjects will be assessed for AEs from the time of their first study treatment until 30 days after the end of their treatment for AEs and until 90 days after their last treatment for serious AEs (study treatment may last for up to 1 year) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Abramson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104
Corey Langer, MD
[email protected]
215-622-3914

Find similar trials in Philadelphia, PA

By research site
Abramson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies